Oncolytics Biotech Inc. (ONCY)
NCM · Healthcare · Biotechnology
$0.80
-2.44%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$95.5M
Shares Outstanding
119.4M
Exchange
NCM
Currency
USD
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.2M | -9.9M | -9.7M | -9.3M |
| Net Income | -4.5M | -10.3M | -9.2M | -9.2M |
| Diluted EPS | $-0.05 | $-0.10 | $nan | $-0.08 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -19.8M | -25.5M | -25.5M | -28.7M |
| Net Income | -18.3M | -20.9M | -22.8M | -28.8M |
| Diluted EPS | $-0.32 | $-0.31 | $-0.29 | $-0.30 |